Featured Innovator

New UH business school dean plans to bring innovation into play

Paul Pavlou has been named as the dean of C. T. Bauer College of Business at the University of Houston. Courtesy of UH

Earlier this year, the University of Houston named a new dean for its C.T. Bauer College of Business. Paul Pavlou officially started his position on July 1, and, even though he has only a few days under his belt at UH, the new dean has a long career in education.

Most recently, Pavlou served as senior associate dean at Temple University within its business program and specializing in data analytics for business. Pavlou also has ties to Houston, as he received his bachelor's from Rice University after receiving a Fulbright Scholarship.

"My life was transformed by higher education," Pavlou says. "So, I feel the need to give back in terms of helping other students — especially of modest means like myself to do well in life and get a good job."

Pavlou has a lot on his plate entering the fall semester. He plans to continue enhancing the college's programs and faculty, while also continue the school's effort to bring in innovation and industry.

The new dean spoke with InnovationMap about what all he sees in Bauer's future.

InnovationMap: How has the first few days on the job been?

Paul Pavlou: So far it's been very exciting. There's so many opportunities for the Bauer College in innovation and technology in new areas that we're considering such health care, analytics, some of the existing areas in energy. So, the goal in my first few days is to talk to as many stakeholders as possible. Try to get to know our existing practices internally, what the opportunities are in the city, and of course, broadly, nationally, internationally. And accordingly, the plan is to see how we can focus on this needs of the industry, how we can create cutting edge programs and prepare the next generation of the workforce, obviously for the city of Houston or the state of Texas nationally and even that globally.

IM: What are some things on your plate that you hope to bring to the college?

PP: In general, one of the areas that I'd like to see us moving into as a college is the digital learning online and how we can do that in a way that it's convenient and flexible for students. Also at the same time, not only maintain the quality of traditional instruction, but also using technology intelligently to provide an even higher quality, more interactive experience for students.

The second thing that I'm very passionate about as well as the notion of experiential learning. I think students should learn from experience and learn by doing. So I would like to see how we can improve this at this college. I'm very happy to report that Bauer has very strong connections to industry, but I would like to make it an even a very strong proposition for the entire college — making sure that, you know, different courses that have an experiential component such as project or working closely with industry.

IM: How is Bauer focusing on the needs the city has for an emerging workforce?

PP: I think increasingly I find and identify more of the city's needs, but I think one of them is the idea of the analytics space and how to use the data. And that's across the board. I talk to people in health care and they say that health care analytics and using data in hospitals is a very important aspect.

More broadly, cutting edge technology is something that is very important not only the city of Houston but beyond. So. we're discussing this idea of artificial intelligence, and how we can play a role in this in a very important emerging area.

One of the things that I would like to see more of is for the University of Houston to work more closely with the business community. We're trying to develop partnerships with the greater Houston partnership and to see what they need as an industry, perhaps for the next generation of workforce.

IM: What role do you see the school playing in the city's innovation ecosystem?

PP: I think we can play a multiple roles. We're an educational organization, so we train the students. We want make sure that through our degrees and offerings have executive programs, and that we satisfy the need for competence and skills needed. And that's why I want us to be on the cutting edge, not only now but in the next five or 10 years.

Second, through our research and through our connections to industry, I want us to be cutting edge in terms of projects and basic research we can actually provide, whether it's analytics, artificial intelligence, or energy. Through our centers and our research, we have world class research faculty in the college. I want us to be out there and to start with the major challenges and help them.

IM: How is the college working with other programs within the university?

PP: One thing I'd like to specify, is that Bauer is obviously a college of business, but I want to take a very broad, multidisciplinary perspective and be very collaborative with the college of medicine, engineering, and nursing. And the idea is to be more open in terms of partnerships with different areas that innovation and new ideas may come into play and provide the business and entrepreneurship components to bring these ideas to market.

------

Portions of this interview have been edited.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted